Price T Rowe Associates Inc Macrogenics Inc Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,337,020 shares of MGNX stock, worth $4.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,337,020
Previous 2,438,050
45.16%
Holding current value
$4.27 Million
Previous $35.9 Million
84.16%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MGNX
# of Institutions
154Shares Held
60.6MCall Options Held
218KPut Options Held
259K-
Bellevue Group Ag Kuesnacht, V89.94MShares$31.7 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY6MShares$19.1 Million0.33% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.14MShares$13.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.31MShares$10.6 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $196M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...